What is the recommended treatment for an acute gout flare in the knee?

Treatment of Acute Gout Flare in the Knee

Systemic corticosteroids are the preferred first-line treatment for an acute gout flare in the knee because they provide efficacy equivalent to NSAIDs while causing fewer adverse effects and costing less. 1

First-Line Treatment Options

Corticosteroids (Preferred)

• Prescribe prednisolone 35 mg orally once daily for 5 days as the standard regimen for acute gout flares in the knee. 1
• Corticosteroids demonstrate comparable pain relief and inflammation control to NSAIDs but with a superior safety profile. 1
• Avoid corticosteroids only in patients with systemic fungal infections or known hypersensitivity to the drug class. 1
• Counsel patients about potential short-term effects including mood changes, elevated blood glucose, immunosuppression, and fluid retention. 1
• For monoarticular knee involvement, intra-articular corticosteroid injection is an appropriate alternative to systemic therapy. 2

NSAIDs (Alternative First-Line)

• All NSAIDs have equivalent efficacy for acute gout—indomethacin offers no advantage over naproxen, ibuprofen, or other agents. 1, 3
• Initiate high-dose, short half-life NSAIDs promptly for optimal response. 2
• Contraindicate NSAIDs in patients with renal disease, heart failure, or cirrhosis due to heightened toxicity risk. 1
• Common adverse effects include dyspepsia and increased risk of gastrointestinal perforation, ulceration, and bleeding. 1
• COX-2 selective inhibitors (COXIBs) provide similar efficacy to non-selective NSAIDs but cause fewer gastrointestinal adverse events. 3

Colchicine (Alternative First-Line)

• Use low-dose colchicine: 1.2 mg followed by 0.6 mg one hour later for acute gout flares. 1
• Low-dose colchicine is as effective as high-dose regimens but causes markedly fewer gastrointestinal side effects (23% vs 77% diarrhea rate). 1
• Colchicine is the most expensive non-biologic anti-inflammatory option for gout. 1
• Avoid colchicine in patients with renal or hepatic impairment who are taking potent CYP3A4 or P-glycoprotein inhibitors (e.g., clarithromycin, ketoconazole). 1
• Typical adverse events include diarrhea, nausea, vomiting, and abdominal cramps. 1

Diagnostic Confirmation in the Knee Joint

• Aspirate the knee joint to identify monosodium urate crystals in synovial fluid for definitive diagnosis, especially important in prosthetic joints where infection must be excluded. 4
• Screen aspirated fluid for crystals regardless of white blood cell count, as gout can present with variable leukocyte counts. 4
• In prosthetic knee joints, acute gout is a rare but important differential diagnosis that can mimic infection. 4

Initiating Urate-Lowering Therapy During the Acute Flare

• Starting urate-lowering therapy (ULT) during an acute gout flare does not prolong the flare duration or increase its severity. 1
• Initiating ULT during the acute episode improves care efficiency and capitalizes on patient motivation to adhere to long-term therapy. 1
• Always provide concomitant anti-inflammatory prophylaxis when starting ULT to prevent recurrent flares. 1
• Acceptable prophylactic agents include colchicine, NSAIDs, or low-dose corticosteroids. 1
• Continue anti-inflammatory prophylaxis for 3–6 months rather than shorter courses of less than 3 months. 1
• After stopping prophylaxis, expect a temporary increase in flare risk (approximately 30% of patients experience flares in the first 3 months post-discontinuation, returning to baseline by month 6). 5

Urate-Lowering Therapy Selection

• Allopurinol is the preferred first-line urate-lowering agent for all patients, including those with moderate-to-severe chronic kidney disease (CKD stage ≥3). 1
• Start allopurinol at ≤100 mg/day (reduce further in CKD stage ≥3) and titrate upward to achieve target serum urate levels. 1
• The maximum FDA-approved dose of allopurinol is 800 mg/day. 1
• Low-dose initiation reduces the risk of allopurinol hypersensitivity syndrome. 1
• Febuxostat is an alternative first-line agent, particularly for patients with asymptomatic hyperuricemia or those intolerant to allopurinol. 6

Critical Pitfalls to Avoid

• Never use high-dose colchicine regimens (e.g., 1.2 mg followed by 0.6 mg hourly for 6 hours)—they provide no additional benefit and cause significantly more gastrointestinal toxicity. 1
• Do not delay ULT initiation in patients with recurrent gout (≥2 episodes per year) or problematic gout (tophi, chronic kidney disease, urolithiasis). 1
• Do not start long-term ULT after a single gout attack or when attacks are infrequent (<2 per year). 1
• Ensure adequate duration of anti-inflammatory therapy and provide thorough patient education about the treatment plan. 2